Der Nervenarzt

, Volume 81, Issue 5, pp 539–548 | Cite as

Akut- und Langzeittherapie der bipolaren Depressionen

Leitthema

Zusammenfassung

Bipolare Depressionen gehen mit erheblichen seelischen Belastungen und einem hohen Suizidrisiko einher; dies macht eine rasche und wirksame Therapie dringend erforderlich. Allerdings gilt auch bei der bipolaren Depression, ähnlich wie bei der Maniebehandlung, die langfristige Prophylaxe schon zu Therapiebeginn im Auge zu behalten. Bei vergleichbarer Wirksamkeit sollten Medikamente mit einem guten Sicherheits- und Verträglichkeitsprofil in jedem Fall den Vorzug erhalten. Zusätzliche Psychotherapie kann sowohl die kurz- als auch langfristige Prognose bipolarer Depressionen deutlich verbessern. Die Elektrokonvulsionstherapie (EKT) hat unverändert ihren Platz bei schweren, therapieresistenten bipolaren Depressionen. Während die EKT in der Hand spezialisierter Zentren liegt, ist die korrekte Diagnosestellung und medikamentöse sowie psychotherapeutische Behandlungseinleitung vorrangige Aufgabe von Haus- und Nervenärzten.

Schlüsselwörter

Bipolare Störung Depression Pharmakotherapie Psychotherapie Elektrokonvulsionstherapie 

Acute and long-term treatment for bipolar depression

Summary

Bipolar depression is linked with substantial burden and a high suicide risk, making a rapid and highly efficacious treatment mandatory. However, similar to mania, aspects of long-term treatment should already be considered at treatment initiation. With comparable efficacy, drugs with a beneficial safety and tolerability profile should be preferred. Additional psychotherapy can also noticeably improve both short- and long-term outcome of bipolar depression. Electroconvulsive therapy (ECT) still has its place in severe, treatment-resistant bipolar depression. Whereas ECT is a domain of specialised centres, correct diagnosis and both pharmacological and psychotherapeutic treatment initiation are essential tasks of primary care practitioners and secondary care psychiatrists.

Keywords

Bipolar disorder Depression Pharmacotherapy Psychotherapy Electroconvulsive therapy 

Notes

Danksagung

Die Autoren bedanken sich bei Frau Heike Brosamler für ihre sekretarielle Unterstützung.

Interessenkonflikt

Der korrespondierende Autor weißt auf folgende Beziehungen: Prof. Dr. Grunze ist als Referent oder Berater für die Firmen Astra Zeneca, BMS, Eli Lilly, Glaxo-SmithKline, Janssen-Cilag, Organon, Pfizer Inc, Sanofi-Aventis, Servier und UBC tätig. Er erhält Drittmittel für Auftragsforschung oder Forschungsunterstützung von Astra Zeneca, Bial, UK National Institute for Mental Health Research, Pfizer Inc, und The Stanley Research Institute.

Literatur

  1. 1.
    Altshuler L, Suppes T, Black D et al (2003) Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 160:1252–1262CrossRefPubMedGoogle Scholar
  2. 2.
    Altshuler LL, Frye MA, Gitlin MJ (2003) Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 53:691–700CrossRefPubMedGoogle Scholar
  3. 3.
    Altshuler LL, Post RM, Hellemann G et al (2009) Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 70(9):1273–1280CrossRefGoogle Scholar
  4. 4.
    Angst F, Stassen HH, Clayton PJ, Angst J (2002) Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 68:167–181CrossRefPubMedGoogle Scholar
  5. 5.
    Bauer M, London ED, Rasgon N et al (2005) Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry 10:456–469CrossRefPubMedGoogle Scholar
  6. 6.
    Bauer MS, Wisniewski SR, Marangell LB et al (2006) Are antidepressants associated with new-onset suicidality in bipolar disorder? a prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 67:48–55CrossRefPubMedGoogle Scholar
  7. 7.
    Bond DJ, Noronha MM, Kauer-Sant’Anna M et al (2008) Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 69:1589–1601CrossRefPubMedGoogle Scholar
  8. 8.
    Bowden CL, Calabrese JR, McElroy SL et al (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex maintenance study group. Arch Gen Psychiatry 57:481–489CrossRefPubMedGoogle Scholar
  9. 9.
    Brecher M, Anderssen H, Paulsson B (2008) Quetiapine in the maintenance treatment of Bipolar I disorder: Combined data from two long-term phase III studies. Bipolar Disord 10 [Suppl 1]:40Google Scholar
  10. 10.
    Cohn JB, Collins G, Ashbrook E, Wernicke JF (1989) A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4:313–322CrossRefPubMedGoogle Scholar
  11. 11.
    Colom F, Vieta E, Martinez-Aran A et al (2003) A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 60:402–407CrossRefPubMedGoogle Scholar
  12. 12.
    Colom F, Vieta E, Sanchez-Moreno J et al (2009) Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry 194:260–265CrossRefPubMedGoogle Scholar
  13. 13.
    Denicoff KD, Smith-Jackson EE, Disney ER et al (1997) Comparative prophylactic efficacy of lithium, carbamazepine and the combination in bipolar disorder. J Clin Psychiatry 58:470–478PubMedGoogle Scholar
  14. 14.
    Frye MA, Grunze H, Suppes T et al (2007) A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 164:1242–1249CrossRefPubMedGoogle Scholar
  15. 15.
    Geddes JR, Burgess S, Hawton K et al (2004) Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161:217–222CrossRefPubMedGoogle Scholar
  16. 16.
    Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4–9CrossRefPubMedGoogle Scholar
  17. 17.
    Geddes JR, The BALANCE investigators and collaborators (2010) Bipolar affective disorder: Lithium/anti-convulsant evaluation (BALANCE) – an international, randomised, open-label trial of combination therapy in relapse prevention in bipolar disorder, type 1. Lancet (in press)Google Scholar
  18. 18.
    Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ (2008) Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 118:347–356CrossRefPubMedGoogle Scholar
  19. 19.
    Goodwin FK, Murphy DL, Dunner DL, Bunney WE (1972) Lithium response in unipolar versus bipolar depression. Am J Psychiatry 129:44–47PubMedGoogle Scholar
  20. 20.
    Goodwin GM, Bowden CL, Calabrese JR et al (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432–441CrossRefPubMedGoogle Scholar
  21. 21.
    Grunze H, Forsthoff A, Born C (2005) Polypharmazie in der Behandlung bipolarer Störungen. In: Messer T, Schmauss M (Hrsg) Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Wien New York, S 81–102Google Scholar
  22. 22.
    Grunze H, Vieta E, Goodwin GM et al (2010) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (in press)Google Scholar
  23. 23.
    Gyulai L, Bowden CL, McElroy SL et al (2003) Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28:1374–1382CrossRefPubMedGoogle Scholar
  24. 24.
    Hartong EG, Moleman P, Hoogduin CA et al (2003) Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 64:144–151PubMedCrossRefGoogle Scholar
  25. 25.
    Medda P, Perugi G, Zanello S et al (2009) Response to ECT in bipolar I, bipolar II and unipolar depression. J Affect Disord 118:55–59CrossRefPubMedGoogle Scholar
  26. 26.
    Möller HJ, Bottlender R, Grunze H et al (2001) Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord 67:141–146CrossRefPubMedGoogle Scholar
  27. 27.
    Müller-Oerlinghausen B, Ahrens B, Felber W (2006) The suicide-preventive and mortality reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in neuropsychiatry: The comprehensive guide. Informa healthcare, Oxfordshire, UK, pp 179–192Google Scholar
  28. 28.
    Müller-Oerlinghausen B, Greil W, Berghöfer A (1997) Die Lithiumtherapie: Nutzen, Risiken, Alternativen. Springer, Berlin HeidelbergGoogle Scholar
  29. 29.
    Nierenberg AA, Ostacher MJ, Calabrese JR et al (2006) Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 163:210–216CrossRefPubMedGoogle Scholar
  30. 30.
    Nolen WA, Weisler RH, Neijber A et al (2009) Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Presented at the 17th European congress of psychiatry, 24–28 January 2009, Lisbon, PortugalGoogle Scholar
  31. 31.
    Sachs GS, Nierenberg AA, Calabrese JR et al (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356:1711–1722CrossRefPubMedGoogle Scholar
  32. 32.
    Sartorius N, Baghai TC, Baldwin DS et al (2007) Antidepressant medications and other treatments of depressive disorders: a CINP Task force report based on a review of evidence. Int J Neuropsychopharmacol 10 [Suppl 1]:1–207Google Scholar
  33. 33.
    Severus WE, Kleindienst N, Seemuller F et al (2008) What is the optimal serum lithium level in the long-term treatment of bipolar disorder–a review? Bipolar Disord 10:231–237CrossRefPubMedGoogle Scholar
  34. 34.
    Sienaert P, Peuskens J (2007) Anticonvulsants during electroconvulsive therapy: review and recommendations. J ECT 23:120–123CrossRefPubMedGoogle Scholar
  35. 35.
    Smith LA, Cornelius VR, Azorin JM et al (2009) Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis. J Affect Disord 122(1):1CrossRefPubMedGoogle Scholar
  36. 36.
    Solomon DA, Keitner GI, Ryan CE, Miller IW (1998) Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. J Clin Psychopharmacol 18:38–49CrossRefPubMedGoogle Scholar
  37. 37.
    Spina E, Pisani F, Perucca E (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 31:198–214CrossRefPubMedGoogle Scholar
  38. 38.
    Stone M, Laughren T, Jones ML et al (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339:b2880CrossRefPubMedGoogle Scholar
  39. 39.
    Tiihonen J, Lonnqvist J, Wahlbeck K et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620–627CrossRefPubMedGoogle Scholar
  40. 40.
    Tohen M, Frank E, Bowden CL et al (2010) The International Society of Bipolar Disorders (ISBD) task force on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord (in press)Google Scholar
  41. 41.
    Tohen M, Vieta E, Calabrese J et al (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079–1088CrossRefPubMedGoogle Scholar
  42. 42.
    Loos ML van der, Mulder PG, Hartong EG et al (2009) Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 70:223–231CrossRefPubMedGoogle Scholar
  43. 43.
    Wu JC, Kelsoe JR, Schachat C et al (2009) Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 66(3):298–301CrossRefPubMedGoogle Scholar
  44. 44.
    Zhang ZJ, Kang WH, Tan QR et al (2007) Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 41:360–369CrossRefPubMedGoogle Scholar
  45. 45.
    Zornberg GL, Pope HG (1993) Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 13:397–408CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Institute of Neuroscience, PsychiatryNewcastle UniversityNewcastle upon Tyne NE1 4LPUK
  2. 2.Psychiatrische Klinik der LMU MünchenMünchenDeutschland

Personalised recommendations